ID
45763
Descripción
Principal Investigator: Wade H. Berrettini, MD, PhD, University of Pennsylvania MeSH: Opioid-Related Disorders,Substance-Related Disorders https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001135 The Starting Treatment with Agonist Replacement Therapy (START) study was a 24-week, open-label, randomized trial of methadone *versus* Suboxone (buprenorphine/naloxone) for the treatment of opioid dependence. Patients were over the age of 18 and met DSM-IV qualifications for opioid dependence. The primary goal of the study was to determine if either medicine was associated with liver toxicity issues in this vulnerable patient population. Liver enzymes were measured at four time points. Urinalysis for opioids, cocaine, cannabis, benzodiazepines, and methamphetamine were performed on a weekly basis. A flexible dosing scheme was used during which physicians could alter medication dose based on withdrawal symptoms and urinalysis results. Neither medication was found to be associated with liver enzyme levels. In version 2 of this study, a text file containing 7704 SNPs with large allele frequency discrepancy as compared to 1000 Genomes is included. Users have the option to exlude these 7704 SNPs.
Link
Palabras clave
Versiones (1)
- 16/6/23 16/6/23 - Chiara Middel
Titular de derechos de autor
Wade H. Berrettini, MD, PhD, University of Pennsylvania
Subido en
16 de junio de 2023
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs001135 Starting Treatment with Agonist Replacement Therapies (START)
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- This subject consent data table informs of subject ID, subject consent group, source repository in which subject originated, ID assigned to the subject by the source repository, and subject's case - control status for opioid dependence.
- This pedigree data table provides subject's family information including the mother and father of the subject. This pedigree table also informs of subject's sex.
- This subject sample mapping data table includes a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. This table also informs of the source repository in which the sample was obtained and the ID assigned to the sample by the source repository.
- This subject phenotypes data table provides information about the abuse and dependency status of the subject for: opioids, cocaine, alcohol, nicotine, cannabis, stimulants, sedatives, and 'other' drugs. It also informs of subject's age, sex, race, live/death status, and the diagnostic system used on the subject.
- This sample attributes data table informs of body site where sample was collected and sample analyte type.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- This subject consent data table informs of subject ID, subject consent group, source repository in which subject originated, ID assigned to the subject by the source repository, and subject's case - control status for opioid dependence.
- This pedigree data table provides subject's family information including the mother and father of the subject. This pedigree table also informs of subject's sex.
- This subject sample mapping data table includes a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. This table also informs of the source repository in which the sample was obtained and the ID assigned to the sample by the source repository.
- This subject phenotypes data table provides information about the abuse and dependency status of the subject for: opioids, cocaine, alcohol, nicotine, cannabis, stimulants, sedatives, and 'other' drugs. It also informs of subject's age, sex, race, live/death status, and the diagnostic system used on the subject.
- This sample attributes data table informs of body site where sample was collected and sample analyte type.
C0680251 (UMLS CUI [1,2])
C0220952 (UMLS CUI [1,2])
C0243161 (UMLS CUI [1,3])
C0242402 (UMLS CUI [1,4])
C0038580 (UMLS CUI [1,5])
C0001779 (UMLS CUI [1,6])
C0680251 (UMLS CUI [2,1])
C0878544 (UMLS CUI [2,2])
C0023895 (UMLS CUI [2,3])
C0281774 (UMLS CUI [2,4])
C0151905 (UMLS CUI [2,5])
C0151904 (UMLS CUI [2,6])
C4489703 (UMLS CUI [2,7])
C0542537 (UMLS CUI [2,8])